Old Web
English
Sign In
Acemap
>
authorDetail
>
Aulde Flechais
Aulde Flechais
Hoffmann-La Roche
Estrogen receptor
Fulvestrant
Oncology
Metastatic breast cancer
Venetoclax
2
Papers
5
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (2)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Results from VERONICA: A randomized, phase II study of second-/third-line venetoclax (VEN) + fulvestrant (F) versus F alone in estrogen receptor (ER)-positive, HER2-negative, locally advanced, or metastatic breast cancer (LA/MBC).
2021
Journal of Clinical Oncology
Geoffrey J. Lindeman
Rebecca Bowen
Katarzyna J. Jerzak
Xinni Song
Thomas Decker
Frances M. Boyle
Steven L. McCune
Anne C Armstrong
Catherine Shannon
Gianfilippo Bertelli
Tharu M. Fernando
Rupal Desai
Kushagra Gupta
Jerry Y. Hsu
Aulde Flechais
Aditya Bardia
Show All
Source
Cite
Save
Citations (4)
Randomized phase II trial of venetoclax + fulvestrant versus fulvestrant in estrogen receptor+, HER2– locally advanced or metastatic breast cancer following recurrence or progression during or after a CDK4/6 inhibitor: VERONICA.
2019
Journal of Clinical Oncology
Geoffrey J. Lindeman
Aditya Bardia
Rebecca Bowen
Aulde Flechais
Guiyuan Lei
Alexandra Hogea
Mehrdad Mobasher
Saeed Rafii
Show All
Source
Cite
Save
Citations (1)
1